Compare ICON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICON | GNPX |
|---|---|---|
| Founded | 2023 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.9M |
| IPO Year | N/A | 2017 |
| Metric | ICON | GNPX |
|---|---|---|
| Price | $1.05 | $4.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.2K | ★ 119.6K |
| Earning Date | 02-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 4754.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.14 |
| 52 Week High | $4.23 | $12.97 |
| Indicator | ICON | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.17 |
| Support Level | N/A | $1.06 |
| Resistance Level | N/A | $9.99 |
| Average True Range (ATR) | 0.00 | 0.88 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 0.00 | 1.87 |
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).